NASDAQ · Health care

Phio Pharmaceuticals Corp. (PHIO)

It posted a net loss of $12.9M. In fiscal 2025 capital spending exceeded operating cash flow by $8M. At June 30, 2026 it held $13M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

Price

$1.01

-0.98% on the day · September 25, 2026

52-week range $0.81 to $4.19

Market cap

$11.7M

What Phio Pharmaceuticals Corp. does

Phio Pharmaceuticals Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PHIO.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$9.2M	-$8.7M	-$1.45	-$8M
2024	n/a	-$7.4M	-$7.2M	-$9.08	-$7.1M
2023	n/a	-$10.8M	-$10.8M	-$46.76	-$10.8M
2022	n/a	-$11.5M	-$11.5M	-$90.82	-$12.3M
2021	n/a	-$13.5M	-$13.3M	-$111.77	-$11.9M
2020	$0	-$8.8M	-$8.8M	-$206.35	-$8.8M

Full financial statements: income, balance sheet and cash flow

Next report expected around November 5, 2026.

Estimated from its filing rhythm: about 91 days after its last report of August 6, 2026, its usual gap. Not a date the company has announced. See the report calendar

Latest SEC filings

What Phio Pharmaceuticals Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 14, 2026
Other event 8-K
August 14, 2026
Annual report to shareholders ARS
August 14, 2026
Additional proxy material DEFA14A
August 14, 2026
Proxy statement DEF 14A
August 6, 2026
Quarterly results 8-K
August 6, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.36 versus -$0.45.
July 21, 2026
Executive or director change 8-K
May 7, 2026
Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.34 versus -$0.41.
May 7, 2026
Quarterly results 8-K
April 8, 2026
Material agreement 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 25, 2026. Insider transactions on SEC

Insider trades

What the people running Phio Pharmaceuticals Corp. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders bought $48.7K worth of shares on the open market in the last 90 days and sold none.

Bought (open market)

$48.7K

last 90 days

Sold

last 90 days

Net bought

45,500

$48.7K

Date	Insider	What	Shares	Price	Value	Filing
September 24, 2026	Bradford Patricia ADirector	Bought	6,500	$1.01	$6.6K	Form 4
September 22, 2026	Bitterman Robert JChairman, Pres. & CEO, Director	Bought	2,000	$1.03	$2.1K	Form 4
September 15, 2026	Bradford Patricia ADirector	Bought	12,000	$1.03	$12.4K	Form 4
September 11, 2026	Carson Lisa CabottChief Financial Officer	Shares withheld for tax	12,888	$1.03	$13.3K	Form 4
September 11, 2026	Bitterman Robert JChairman, Pres. & CEO, Director	Shares withheld for tax	68,550	$1.03	$70.6K	Form 4
August 19, 2026	Plott Ronald ToddDirector	Bought	15,000	$1.14	$17.1K	Form 4
August 18, 2026	Bitterman Robert JChairman, Pres. & CEO, Director	Bought	10,000	$1.06	$10.6K	Form 4
June 26, 2026	Bitterman Robert JChairman, Pres. & CEO, Director	Bought	10,000	$0.99	$9.9K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns PHIO

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
CVI Investments, Inc.13G, passive with 1 related filers	9.9%	1,194,719	February 17, 2026
Mitchell P. Kopin13G, passive with 2 related filers	9.1%	1,142,556	February 13, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

4 insiders reported holding 525,134 shares in total, about $530.4K at the last price.

Holder	Shares	As of
Bitterman Robert JChairman, Pres. & CEO, Director	364,871	September 22, 2026
Carson Lisa CabottChief Financial Officer	81,112	September 11, 2026
Bradford Patricia ADirector	64,151	September 24, 2026
Plott Ronald ToddDirector	15,000	August 19, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about PHIO

What does Phio Pharmaceuticals Corp. do?

Phio Pharmaceuticals Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PHIO.

Is Phio Pharmaceuticals Corp. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $12.9M.

When did Phio Pharmaceuticals Corp. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 25, 2026.

Similar companies

Compare PHIO with

Compare PHIO with any company

Follow PHIO

Get an email when Phio Pharmaceuticals Corp. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PHIO: get an email when it files

Where the numbers come from

Financial figures are the values Phio Pharmaceuticals Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.